August 17, 2021 Celebrating National Nonprofit Day and Sharing C-Path Updates As we observe National Nonprofit Day and recognize the invaluable effort nonprofits put towards making an impact in our communitie
August 7, 2021 Antenatal and perinatal factors influencing neonatal blood pressure: a systematic review
August 5, 2021 C-Path Appoints Clinical Outcome Assessment Expert as New Executive Director Sonya Eremenco will lead C-Path’s PRO Consortium TUCSON, Ariz., August 5, 2021— Critical Path Institute (C-Path) announced it
August 1, 2021 A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation Ahamadi M, Mehrotra N, Hanan N, Lai Yee K, Gheyas F, Anton J, Bani M, Boroojerdi B, Smit H, Weidemann J, Macha S, Thuillier V...
July 21, 2021 View Now | How RDCA-DAP Can Help Inform Optimal Trial Design in Progressive Rare Disease When: July 21, 2021, 12 p.m. ET Case Study: Northstar Ambulatory Assessment as an outcome assessment in Duchenne muscular
July 20, 2021 Digital Health Technologies Hold Key to New Parkinson’s Treatments Global stakeholders come together to collaborate with urgency to address unmet needs for Parkinson’s therapies. TUCSON, Ariz., J
July 16, 2021 View Now | RDCA-DAP Webinar Series: Value of Integrated Data and Analytics in Rare Disease Drug Development When: June 16, 2021, 12 p.m. ET Case Study: Modeling disease progression in polycystic kidney disease to inform tr
July 15, 2021-July 26, 2021 VIEW NOW | Design of Clinical Trials in New-Onset Type 1 Diabetes: Regulatory Considerations for Drug Development Critical Path Institute held a free virtual workshop, Design of Clinical Trials in New-Onset Type 1 Diabetes: Regulatory Cons
July 15, 2021 Launch of UNITE4TB Partnership Marks a New Era in Tuberculosis Treatment Development The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiat
July 8, 2021 Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective Stephenson D, Badawy R, Mathur S, Tome M, Rochester L. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials...
